Top

Published in:

01-09-2014 | Original Article

Hepcidin and GDF15 in anemia of multiple myeloma

Authors: Shuchong Mei, Huaquan Wang, Rong Fu, Wen Qu, Limin Xing, Guojin Wang, Jia Song, Hong Liu, Lijuan Li, Xiaoming Wang, Yuhong Wu, Jin Guan, Erbao Ruan, Zonghong Shao

Published in: International Journal of Hematology | Issue 3/2014

Abstract

Multiple myeloma (MM) is a malignant disease of plasma cells and is often accompanied by anemia which may influence its progression and survival. The mechanism of anemia of chronic disease (ACD) in which iron homeostasis is impaired underlies that of MM-related anemia. In this study, we analyzed the role of hepcidin which is the main mediator of ACD and ACD-related cytokines in peripheral blood of MM patients. We showed that HAMP mRNA and growth differentiation factors 15 (GDF15) mRNA expressions in peripheral blood mononuclear cells (PBMCs) and plasma hepcidin, GDF15, interleukin-6 and erythropoietin in MM patients all increased significantly as compared to those in controls. In MM patients, the expression of HAMP mRNA showed a positive correlation with serum ferritin level, and a negative correlation with hemoglobin level. The levels of plasma hepcidin and GDF15 were significantly decreased in MM patients who achieved complete remission after six cycles VD (bortezomib + dexamethasone) regimen chemotherapy. These data indicated that overexpression of HAMP mRNA in PBMCs significantly correlated with increased plasma hepcidin level and may be involved in the pathogenesis of MM-related anemia. Furthermore, the levels of plasma hepcidin and GDF15 may be valuable in assessing the progress of MM.

Robert A, Kyleand S, Rajkumar V, et al. Multiple myeloma. Blood. 2008;111:2962–72.CrossRef

Caravita T, Siniscalchi A, Montanaro M, et al. High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients. Int J Hematol. 2009;90:270–2.PubMedCrossRef

Cucuianu A, Patiu M, Rusu A. Hepcidin and multiple myeloma related anemia. Med Hypotheses. 2006;66:352–4.PubMedCrossRef

Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma. 2003;4(Suppl 1):S23–9.PubMedCrossRef

Silvestris F, Tucci M, Quatraro C, et al. Recent advances in understanding the pathogenesis of anemia in multiple myeloma. Int J Hematol. 2003;78:121–5.PubMedCrossRef

Goodnough LT. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol. 2007;35:167–72.PubMedCrossRef

Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096–101.PubMedCrossRef

Liu X, Xie W, Liu P, et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia–reperfusion. Life Sci. 2006;78:2255–64.PubMedCrossRef

Peyssonnaux C, Zinkernagel AS, Datta V, et al. TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood. 2006;107:3727–32.PubMedCentralPubMedCrossRef

10.

Theurl I, Theurl M, Seifert M, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008;111:2392–9.PubMedCrossRef

11.

Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood. 2008;112:4292–7.PubMedCrossRef

12.

Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14:3262–7.PubMedCrossRef

13.

Birgegård G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol. 2006;77:378–86.PubMedCentralPubMedCrossRef

14.

Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood. 2003;101:2461–3.PubMedCrossRef

15.

Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Investig. 2004;113:1271–6.PubMedCentralPubMedCrossRef

16.

Truksa J, Peng H, Lee P, Beutler E. Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br J Haematol. 2007;139:138–47.PubMedCrossRef

17.

Maes K, Nemeth E, Roodman GD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010;116:3635–44.PubMedCentralPubMedCrossRef

18.

Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood. 2008;112:1503–9.PubMedCrossRef

19.

Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41:478–81.PubMedCrossRef

20.

Andriopoulos B, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41:482–7.PubMedCentralPubMedCrossRef

21.

Katodritou E, Ganz T, Terpos E, et al. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. Am J Hematol. 2009;84:524–6.PubMedCrossRef

22.

Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108:3204–9.PubMedCentralPubMedCrossRef

23.

Tarkun P, Birtas Atesoglu E, Mehtap O, et al. Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients. Acta Haematol. 2013;131:173–8.PubMedCrossRef

24.

Corre J, Labat E, Espagnolle N, et al. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res. 2012;72:1395–406.PubMedCrossRef

25.

Tanno T, Lim Y, Wang Q, et al. Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood. 2014;123:725–33.PubMedCrossRef

26.

Tamary H, Shalev H, Perez-Avraham G. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood. 2008;112:5241–4.PubMedCentralPubMedCrossRef

27.

Aizawa S, Harada T, Kanbe E, et al. Ineffective erythropoiesis in mutant mice with deficient pyruvate kinase activity. Exp Hematol. 2005;33:1292–8.PubMedCrossRef

28.

Kempf T, Horn-Wichmann R, Brabant G, et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem. 2007;53:284–91.PubMedCrossRef

29.

Akiyama M, Okano K, Fukada Y, et al. Macrophage inhibitory cytokine MIC-1 is upregulated by short-wavelength light in cultured normal human dermal fibroblasts. FEBS Lett. 2009;583:933–7.PubMedCrossRef

30.

Ago T, Kuroda J, Pain J, et al. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res. 2010;106:1253–64.PubMedCentralPubMedCrossRef

31.

Léon K, Grace J, Elizabeta N, et al. The erythroid factor erythroferrone and its role in iron homeostasis. Blood. 2013;122:21–4.

Title: Hepcidin and GDF15 in anemia of multiple myeloma
Authors: Shuchong Mei
Huaquan Wang
Rong Fu
Wen Qu
Limin Xing
Guojin Wang
Jia Song
Hong Liu
Lijuan Li
Xiaoming Wang
Yuhong Wu
Jin Guan
Erbao Ruan
Zonghong Shao
Publication date: 01-09-2014
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 3/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-014-1626-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Role of tissue-specific AT-rich DNA sequence-binding proteins in lymphocyte differentiation

Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload

Three different histological subtypes of Epstein–Barr virus-negative post-transplant lymphoproliferative disorder in a patient with hepatitis C infection

Guest editorial: Molecular mechanisms of lymphocyte development: recent findings

Ikaros fingers on lymphocyte differentiation

Hemorrhagic hepatic cyst after allogeneic bone marrow transplantation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer